RefleXion Medical is on a mission to create a new cancer treatment modality through biological guidance. By leveraging positron emission tomography (PET) in a novel way, RefleXion’s patented technology causes tumors to continuously signal their location during treatment, potentially revolutionizing cancer care.
Potential Meets Values & Execution
A relevant mission is the cornerstone of any game-changing company, but having the values to execute is the key to long-term success. At RefleXion, our core values are present in everything we do.
Significant Innovation in Localized Cancer Treatment
With a bold mission and dedication to build a high-performing business, RefleXion has inspired the confidence of blue-chip investors, all committed to advancing a new modality in cancer care. RefleXion has raised over $160M in funding from premier investment firms including TPG Growth / The Rise Fund, Sofinnova Partners, KCK Group, Pfizer Venture Investments, Venrock, Johnson & Johnson Innovation, T. Rowe Price Associates and GT Healthcare Capital Partners. The National Cancer Institute (NCI) also provided grant funding through its Small Business Innovation Research (SBIR) Program.